title: Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.
abstract: The introduction of molecularly targeted drugs has increased the risk of reactivation of hepatitis B virus (HBV), which is a potentially fatal complication following anticancer chemotherapy even in patients who have previously resolved their HBV infection. CC chemokine receptor 4 (CCR4) has been identified as a novel molecular target in antibody therapy for patients with adult T-cell leukemia-lymphoma (ATL) and peripheral T-cell lymphoma, and the humanized anti-CCR4 monoclonal antibody mogamulizumab has been developed. We reported HBV reactivation of an ATL patient with previously resolved HBV infection after mogamulizumab treatment in a dose-finding study for this antibody. Our retrospective analysis using preserved samples also revealed the detailed kinetics of HBV DNA levels before and just after HBV reactivation.
authors.affiliation: Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan.
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Nakano
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kusumoto
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishida
authors.forename: Shogo
authors.initials: S
authors.lastname: Takeuchi
authors.forename: Yoshifusa
authors.initials: Y
authors.lastname: Takatsuka
authors.forename: Shiro
authors.initials: S
authors.lastname: Akinaga
authors.forename: Masashi
authors.initials: M
authors.lastname: Mizokami
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ueda
authors.forename: Atae
authors.initials: A
authors.lastname: Utsunomiya
keywords: CC chemokine receptor 4; hepatitis B virus; mogamulizumab; reactivation